Response to the Letter Regarding “Methodological Considerations in Real‐World Evaluation of Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma”
Data supporting the findings of this study are available from the corresponding author upon reasonable request, subject to institutional review board approval and execution of appropriate data sharing agreements.
Authors
- Takashi Kumada (ORCID: https://orcid.org/0000-0003-2211-495X)
- Toshifumi Tada (ORCID: https://orcid.org/0000-0002-0976-6761)
- Tomomitsu Matono (ORCID: https://orcid.org/0009-0001-7114-5464)
- the RELPEC Group
Institutions
- Himeji Medical Center (JP)
- Himeji Red Cross Hospital (JP)
- Gifu Kyoritsu University (JP)
- Kobe University (JP)
Publication Details
- Journal
- Journal of Gastroenterology and Hepatology
- Published
- 2026-08-18
- DOI
- https://doi.org/10.1111/jgh.70674
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00